{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:42:54Z","timestamp":1769114574709,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.bmcl.2022.128577","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T15:13:17Z","timestamp":1642605197000},"page":"128577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood\u2013brain barrier"],"prefix":"10.1016","volume":"59","author":[{"given":"Paul W.","family":"Manley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Huth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saliha","family":"Moussaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Schoepfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128577_b0005","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1042\/BC20080020","article-title":"Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells","volume":"100","author":"Sirvenwylit","year":"2008","journal-title":"Biol Cell."},{"key":"10.1016\/j.bmcl.2022.128577_b0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1242\/jcs.175521","article-title":"Multifunctional Abl kinases in health and disease","volume":"129","author":"Khatri","year":"2016","journal-title":"J Cell Sci."},{"key":"10.1016\/j.bmcl.2022.128577_b0015","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0896-6273(00)80646-7","article-title":"Essential roles for the Abl and Arg tyrosine kinases in neurulation","volume":"21","author":"Koleske","year":"1998","journal-title":"Neuron."},{"key":"10.1016\/j.bmcl.2022.128577_b0020","series-title":"Abl Family Kinases in Development and Disease. Molecular Biology Intelligence Unit","article-title":"Abelson Family Protein Tyrosine Kinases and the Formation of Neuronal Connectivity","author":"Thompson","year":"2006"},{"key":"10.1016\/j.bmcl.2022.128577_b0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12031-011-9588-1","article-title":"c-Abl in neurodegenerative disease","volume":"45","author":"Schlatterer","year":"2011","journal-title":"J Mol Neurosci."},{"key":"10.1016\/j.bmcl.2022.128577_b0030","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.mcn.2017.10.007","article-title":"Corticosteroid-induced dendrite loss and behavioral deficiencies can be blocked by activation of Abl2\/Arg kinase","volume":"85","author":"Shapiro","year":"2017","journal-title":"Mol Cell Neurosci."},{"key":"10.1016\/j.bmcl.2022.128577_b0035","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1083\/jcb.201812144","article-title":"Regulation of MT dynamics via direct binding of an Abl family kinase","volume":"218","author":"Hu","year":"2019","journal-title":"J Cell Biol."},{"key":"10.1016\/j.bmcl.2022.128577_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2020.00242","article-title":"Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease","author":"Benn","year":"2020","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.bmcl.2022.128577_b0045","doi-asserted-by":"crossref","first-page":"e12044","DOI":"10.1002\/trc2.12044","article-title":"Targeting dementias through cancer kinases inhibition","volume":"6","author":"Fagiani","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.bmcl.2022.128577_b0050","doi-asserted-by":"crossref","DOI":"10.1186\/s13064-020-00144-8","article-title":"The first quarter of the C-terminal domain of Abelson regulates the WAVE regulatory complex and Enabled in axon guidance","volume":"15","author":"Cheong","year":"2020","journal-title":"Neural Dev."},{"key":"10.1016\/j.bmcl.2022.128577_b0055","doi-asserted-by":"crossref","unstructured":"La Barbera L, Vedele F, Nobili A, Krashia P, Spoleti E, Latagliata EC, Cutuli D, Cauzzi E, Marino R, Viscomi MT, Petrosini L, Puglisi-Allegra S, Melone M, Keller F, Mercuri NB, Conti F, D'Amelio M. Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer's Disease. Prog Neurobiol. 2021;5:102031. https:\/\/doi: 10.1016\/j.pneurobio.2021.102031.","DOI":"10.1016\/j.pneurobio.2021.102031"},{"key":"10.1016\/j.bmcl.2022.128577_b0060","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10571-020-00858-7","article-title":"Abelson Kinases Mediate the Depression of Spontaneous Synaptic Activity Induced by Amyloid Beta 1\u201342 Peptides","volume":"41","author":"Reichenstein","year":"2021","journal-title":"Cell Mol Neurobiol."},{"key":"10.1016\/j.bmcl.2022.128577_b0065","doi-asserted-by":"crossref","first-page":"166089","DOI":"10.1016\/j.bbadis.2021.166089","article-title":"c-Abl activates RIPK3 signaling in Gaucher disease","volume":"1867","author":"Ya\u00f1ez","year":"2021","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"10.1016\/j.bmcl.2022.128577_b0070","article-title":"Efficacy of Nilotinib in Patients with Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA","author":"Simuni","year":"2020","journal-title":"Neurology."},{"key":"10.1016\/j.bmcl.2022.128577_b0075","doi-asserted-by":"crossref","unstructured":"Wu J, Xu X, Zheng L, Mo J, Jin X, Bao Y. Nilotinib inhibits microglia-mediated neuroinflammation to protect against dopaminergic neuronal death in Parkinson's disease models. Int Immunopharmacol. 2021;99 108025. https:\/\/doi.org\/10.1016\/j.intimp.2021.108025.","DOI":"10.1016\/j.intimp.2021.108025"},{"key":"10.1016\/j.bmcl.2022.128577_b0080","doi-asserted-by":"crossref","first-page":"102070","DOI":"10.1016\/j.pneurobio.2021.102070","article-title":"\u03b1-Synuclein aggregates induce c-Abl activation and dopaminergic neuronal loss by a feed-forward redox stress mechanism","author":"Ghosh","year":"2021","journal-title":"Prog Neurobiol."},{"key":"10.1016\/j.bmcl.2022.128577_b0085","first-page":"1","article-title":"Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia","volume":"28","author":"Manley","year":"2018","journal-title":"Top Med Chem."},{"key":"10.1016\/j.bmcl.2022.128577_b0090","doi-asserted-by":"crossref","first-page":"10030","DOI":"10.1021\/acs.jmedchem.6b00618","article-title":"Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer","volume":"59","author":"Heffron","year":"2016","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128577_b0095","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature."},{"key":"10.1016\/j.bmcl.2022.128577_b0100","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128577_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","author":"Manley","year":"2020","journal-title":"Leuk Res."},{"key":"10.1016\/j.bmcl.2022.128577_b0110","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A Phase III, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After \u22652 Prior TKIs","volume":"178","author":"R\u00e9a","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.bmcl.2022.128577_b0115","doi-asserted-by":"crossref","first-page":"33486","DOI":"10.1073\/pnas.2007991117","article-title":"The ABL2 kinase regulates an HSF1-dependent transcriptional program required for lung adenocarcinoma brain metastasis","volume":"117","author":"Hoj","year":"2021","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.bmcl.2022.128577_b0120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/00498254.2019.1594449","article-title":"Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects","volume":"50","author":"Tran","year":"2020","journal-title":"Xenobiotica."},{"key":"10.1016\/j.bmcl.2022.128577_b0125","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","article-title":"Extended kinase profile and properties of the protein kinase inhibitor nilotinib","volume":"1804","author":"Manley","year":"2010","journal-title":"Biochim Biophys Acta."},{"key":"10.1016\/j.bmcl.2022.128577_b0130","doi-asserted-by":"crossref","first-page":"105115","DOI":"10.1016\/j.phrs.2020.105115","article-title":"Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy","volume":"161","author":"Rudraraju","year":"2020","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.bmcl.2022.128577_b0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol Dis."},{"key":"10.1016\/j.bmcl.2022.128577_b0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Bloodbrain barrier: from physiology to disease and back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol Rev."},{"key":"10.1016\/j.bmcl.2022.128577_b0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The Blood-Brain Barrier: Bottleneck in Brain Drug Development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx."},{"key":"10.1016\/j.bmcl.2022.128577_b0150","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1021\/jm060642i","article-title":"Structure-Brain Exposure Relationships","volume":"49","author":"Hitchcock","year":"2006","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128577_b0155","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/cn100007x","article-title":"Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem Neurosci."},{"key":"10.1016\/j.bmcl.2022.128577_b0160","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s11033-021-06155-w","article-title":"ABC transporter superfamily. An updated overview, relevance in cancer multidrug resistance and perspectives with personalized medicine","volume":"48","author":"Juan-Carlos","year":"2021","journal-title":"Mol Biol Rep."},{"key":"10.1016\/j.bmcl.2022.128577_b0165","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1517\/17425255.2016.1168804","article-title":"ABC transporters at the blood-brain barrier","volume":"12","author":"Mahringer","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"10.1016\/j.bmcl.2022.128577_b0170","doi-asserted-by":"crossref","first-page":"13423","DOI":"10.18632\/oncotarget.24393","article-title":"The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro","volume":"9","author":"Eadie","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.bmcl.2022.128577_b0175","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/leu.2017.264","article-title":"O'Hare T Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib","volume":"31","author":"Qiang","year":"2017","journal-title":"Leukemia."},{"key":"10.1016\/j.bmcl.2022.128577_b0180","first-page":"258","article-title":"Effect of dimethyl sulfoxide on blood-brain barrier integrity following middle cerebral artery occlusion in the rat","volume":"96","author":"Kleindienst","year":"2006","journal-title":"Acta Neurochir."},{"key":"10.1016\/j.bmcl.2022.128577_b0185","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature."},{"key":"10.1016\/j.bmcl.2022.128577_b0190","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature."},{"key":"10.1016\/j.bmcl.2022.128577_b0195","first-page":"2100","article-title":"KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts","volume":"9","author":"Andersson","year":"1995","journal-title":"Leukemia."},{"key":"10.1016\/j.bmcl.2022.128577_b0200","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1620\/tjem.209.169","article-title":"Cloning and characterization of the novel chimeric gene p53\/FXR2 in the acute megakaryoblastic leukemia cell line CMK11-5","volume":"209","author":"Kanezaki","year":"2006","journal-title":"Tohoku J Exp Med."},{"key":"10.1016\/j.bmcl.2022.128577_b0205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00441-001-0510-y","article-title":"Establishment and characterization of four human pancreatic carcinoma cell lines. Genetic alterations in the TGFBR2 gene but not in the MADH4 gene","volume":"308","author":"Ku","year":"2002","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.bmcl.2022.128577_b0210","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11626-999-0090-9","article-title":"Establishment of an alpha-fetoprotein-producing cell line derived from gastric cancer","volume":"35","author":"Matsuda","year":"1999","journal-title":"In Vitro Cell Dev Biol Anim."},{"key":"10.1016\/j.bmcl.2022.128577_b0215","doi-asserted-by":"crossref","first-page":"102837","DOI":"10.1016\/j.ebiom.2020.102837","article-title":"Machine learning guided association of adverse drug reactions with in vitro target-based pharmacology","volume":"57","author":"Ietswaart","year":"2020","journal-title":"EBioMedicine."},{"key":"10.1016\/j.bmcl.2022.128577_b0220","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0014-5793(94)80368-4","article-title":"Human \u03bc opiate receptor: cDNA and genomic clones, pharmacologic characterization and chromosomal assignment","volume":"338","author":"Wang","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bmcl.2022.128577_b0225","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.vascn.2004.04.001","article-title":"The [3H]-dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering[K+]o","volume":"50","author":"Diaz","year":"2004","journal-title":"J Pharmacol Toxicol Methods."},{"key":"10.1016\/j.bmcl.2022.128577_b0230","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/pharmaceutics12010020","article-title":"ABC transporters at the blood\u2013brain interfaces, their study models, and drug delivery implications in gliomas","volume":"12","author":"Gomez-Zepeda","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.bmcl.2022.128577_b0235","doi-asserted-by":"crossref","unstructured":"Slater B, McCormack A, Avdeef A, Comer JEA. PH-Metric logP.4. Comparison of Partition Coefficients Determined by HPLC and Potentiometric Methods to Literature Values. J Pharm Sci. 1994;83:1280\u20131283. https:\/\/doi.org\/https:\/\/doi.org\/10.1002\/jps.2600830918.","DOI":"10.1002\/jps.2600830918"},{"key":"10.1016\/j.bmcl.2022.128577_b0240","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejps.2016.06.024","article-title":"Optimised method to estimate octanol water distribution coefficient (logD) in a high throughput format","volume":"92","author":"Low","year":"2016","journal-title":"Eur J Pharm Sci."},{"key":"10.1016\/j.bmcl.2022.128577_b0245","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1021\/jm000942e","article-title":"Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties","volume":"43","author":"Ertl","year":"2000","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128577_b0250","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1002\/jps.20913","article-title":"Development of a High Throughput Equilibrium Solubility Assay Using Miniaturized Shake-Flask Method in Early Drug Discovery","volume":"96","author":"Zhou","year":"2007","journal-title":"J Pharm Sci."},{"key":"10.1016\/j.bmcl.2022.128577_b0255","doi-asserted-by":"crossref","unstructured":"Saka R, Chella N, Khan W. Development of Imatinib Mesylate-Loaded Liposomes for Nose to Brain Delivery: In Vitro and In Vivo Evaluation. AAPS PharmSciTech 2021 22:5.","DOI":"10.1208\/s12249-021-02072-0"},{"key":"10.1016\/j.bmcl.2022.128577_b0260","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1021\/acsbiomaterials.1c00555","article-title":"Glutathione Liposomes Carrying Ceftriaxone, FK506, and Nilotinib to Control Overexpressed Dopamine Markers and Apoptotic Factors in Neurons","volume":"7","author":"Kuo","year":"2021","journal-title":"ACS Biomater Sci Eng."},{"key":"10.1016\/j.bmcl.2022.128577_b0265","doi-asserted-by":"crossref","unstructured":"Pratt J, Venkatraman N, Brinker A, Xiao Y, Blasberg J, Thompson DC, Bourner M. Use of zinc finger nuclease technology to knock out efflux transporters in C2BBE1 cells. Curr Protoc Toxicol. 2012;52:23.2.1\u201322. https:\/\/doi.org\/10.1002\/0471140856.tx2302s52.","DOI":"10.1002\/0471140856.tx2302s52"},{"key":"10.1016\/j.bmcl.2022.128577_b0270","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/FPC.0b013e328360d10c","article-title":"ABCB1 single nucleotide polymorphisms (1236C < T, 2677G< T, and 3435C < T) do not affect transport activity of human P-glycoprotein","volume":"23","author":"Dickens","year":"2013","journal-title":"Pharmacogenet Genomics."},{"key":"10.1016\/j.bmcl.2022.128577_b0275","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.xphs.2021.01.029","article-title":"Predicting Oral Absorption for Compounds Outside the Rule of Five Property Space","volume":"110","author":"Huth","year":"2021","journal-title":"J Pharm Sci."}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22000531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22000531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:45:01Z","timestamp":1760773501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22000531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":55,"alternative-id":["S0960894X22000531"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128577","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood\u2013brain barrier","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128577"}}